Natural product derivatives for inhibiting cellular necroptosis, ferroptosis and oxytosis

A combination product comprising:

• (i) at least one compound of the following general formula (I):
• or a pharmaceutically acceptable salt and/or solvate thereof, wherein:
• X1 represents a (C1-C6)alkyl an aryl, an aryl-(C1-C6)alkyl group or an ORX group, wherein RX is selected from a (C1-C6)alkyl, an aryl and an aryl-(C1-C6)alkyl group,
• X2 and X3 each represent, independently of each other, a hydrogen atom or a (C1-C6)alkyl group,
• Y1, Y2 and Y3 each represent, independently of each other, a hydrogen atom, a (C1-C6)alkyl, an aryl, an aryl-(C1-C6)alkyl group, an OH or an ORY group,
• with at least one of Y1, Y2 and Y3 representing a (C1-C6)alkyl, an aryl, an aryl-(C1-C6)alkyl group or an ORY group, wherein
• RY is selected from a (C1-C6)alkyl, an aryl and an aryl-(C1-C6)alkyl group, and
• (ii) at least another active ingredient selected from the group consisting of another cellular necroptosis inhibitor, an apoptosis inhibitor, an autophagy inhibitor, a ferroptosis inhibitor, an inhibitor of mitochondrial permeability transition (MPT) pore-dependent necrosis, a cyclophilin inhibitor, a Cyclin-dependent kinase 5 (CDK5) inhibitor, a parthanatos inhibitor, a thrombin inhibitor, an antioxidant an inflammatory inhibitor and combinations thereof,
• separate from the at least one compound of formula (I),
• for simultaneous, separate or sequential administration.